Changes in serum CXCL13 levels are associated with outcomes of colorectal cancer patients undergoing first-line oxaliplatin-based treatment

Cabrero-de Las Heras, Sara; Martínez Bosch, Neus; Nieva, Maria; Navarro, Pilar; Montagut Viladot, Clara; Martínez-Balibrea, Eva

doi:http://dx.doi.org/10.1016/j.biopha.2024.116857

Changes in serum CXCL13 levels are associated with outcomes of colorectal cancer patients undergoing first-line oxaliplatin-based treatment

Llicència

Citació

Cabrero-de Las Heras S, Hernández-Yagüe X, González A, Losa F, Soler G, Bugés C, et al. Changes in serum CXCL13 levels are associated with outcomes of colorectal cancer patients undergoing first-line oxaliplatin-based treatment. Biomed Pharmacother. 2024 Jul;176:116857. DOI: 10.1016/j.biopha.2024.116857

Resum

Metastatic colorectal cancer (mCRC) currently lacks reliable biomarkers for precision medicine, particularly for chemotherapy-based treatments. This study examines the behavior of 11 CXC chemokines in the blood of 104 mCRC patients undergoing first-line oxaliplatin-based treatment to pinpoint predictive and prognostic markers. Serum samples were collected before treatment, at response evaluation (EVAR), and at disease progression or last follow-up. Chemokines were assessed in all samples using a Luminex® custom panel. CXCL13 levels increased at EVAR in responders, while in non-responders it decreased. Increasing levels of CXCL13 at EVAR, independently correlated with improved progression-free survival (PFS) and overall survival (OS). Nanostring® analysis in primary tumor samples showed CXCL13 gene expression's positive correlation not only with gene profiles related to an immunogenic tumor microenvironment, increased B cells and T cells (mainly CD8+) but also with extended OS. In silico analysis using RNAseq data from liver metastases treated or not with neoadjuvant oxaliplatin-based combinations, and deconvolution analysis using the MCP-counter algorithm, confirmed CXCL13 gene expression's association with increased immune infiltration, improved OS, and Tertiary Lymphoid Structures (TLSs) gene signatures, especially in neoadjuvant-treated patients. CXCL13 analysis in serum from 36 oxaliplatin-treated patients from the METIMMOX study control arm, reported similar findings. In conclusion, the increase of CXCL13 levels in peripheral blood and its association with the formation of TLSs within the metastatic lesions, emerges as a potential biomarker indicative of the therapeutic efficacy in mCRC patients undergoing oxaliplatin-based treatment.